Identification of Early and Late Responders to Anti-IL-13 Antibody Tralokinumab in Atopic Dermatitis: A Real-World Japanese Study.

Tralokinumab, an anti-IL-13 antibody, is an effective treatment for patients with atopic dermatitis (AD). However, predictive factors for responders to tralokinumab remain unclear in real-world practice. This study aimed to identify predictive factors for early and late responders to tralokinumab treatment.

Delayed Contrast Medium Excretion Due to Renal Failure After an Emergency Mechanical Thrombectomy for Acute Cerebral Infarction.

We report a case in which mechanical thrombectomy (MT) was performed on a patient with cerebral infarction and renal failure, and contrast leakage remained on postoperative head computed tomography (CT) scans for more than 24 hours. A 75-year-old woman with a medical history of chronic renal failure due to diabetic nephropathy was admitted to the cardiology department of our hospital with chronic heart failure. During hospitalization, her diabetic nephropathy worsened.

Predictive factors for responders to deucravacitinib treatment in patients with psoriasis.

The tyrosine kinase 2 inhibitor deucravacitinib is therapeutically effective for psoriasis. However, predictive factors for high responses to deucravacitinib have not been examined in a real-world clinical study. Our study aimed to identify predictive factors for responders to deucravacitinib.

Long-term effectiveness and safety of deucravacitinib in psoriasis: A 52-week real-world study of genital, scalp, and nail lesions.

Background: The long-term (around 1-year) effectiveness and safety of deucravacitinib for the treatment of psoriasis have not been extensively studied in real-world settings, particularly in difficult-to-treat areas, such as the genital, scalp, and nail regions.

Objectives: To evaluate the 52-week real-world effectiveness and safety of deucravacitinib in patients with moderate-to-severe psoriasis of the genital, scalp, and nail regions.

Methods: This prospective study analyzed 104 patients with moderate-to-severe plaque psoriasis treated with deucravacitinib.